More than 25 participants use Affymetrix’ integrated genomics solution to accelerate research on more than 10 types of cancer SANTA CLARA, Calif.–Affymetrix Inc. (Nasdaq:AFFX – News) today extended its Collaborations in Cancer Research Program (CCRP) to North America, forming an alliance between Affymetrix and 25 leading cancer researchers. The expansion builds on the success of the European CCRP, launched in April 2007. All of the researchers in the program are using Affymetrix’ integrated genomics solution to accelerate research on more than 10 types of cancer. The Affymetrix integrated genomics solution combines copy number data from the SNP Array 6.0 and expression information from the Human Exon 1.0 ST Array to deliver the most comprehensive view of the cancer genome. This integrated genomics approach accelerates the discovery and validation of candidate genes associated with the disease. A better understanding of the molecular basis of cancer will enable researchers to develop more effective, personalized treatments for a disease that currently costs Americans more than $72 billion a year1. CCRP participants were selected on the basis of past contributions to their respective fields and potential to make significant advancements in cancer research. The Affymetrix integrated solution provides researchers with a deeper understanding of the cancer genome by incorporating genome-wide expression, exon and alternative splice information, as well as genotype, copy number and loss of heterozygosity data from just two arrays. “We are using the SNP 6.0 arrays to obtain the most comprehensive profile of genomic abnormalities aimed at discovering novel molecular targets,” said Tak Mak Wah, Ph.D., professor at the Department of Medical Biophysics, University of Toronto. “The ability to integrate the exon and SNP array data will help us identify candidate driver genes underlying these genomic abnormalities and speed up their validation.” “The genomics of cancer disparities among racial minorities is a rapidly evolving field,” said Norman H. Lee, Ph.D., professor at the Department of Pharmacology and Physiology, George Washington University Medical Center. “We are excited to be partnering with Affymetrix to identify and investigate new molecular targets as a prelude to reduce cancer health disparities.” “The continued advancement of microarray technologies has enabled characterization of the cancer genome in unprecedented detail,” said William M. Lin, computational biologist at the Broad Institute of M.I.T. and Harvard and Yale University, School of Medicine. “While this development simultaneously presents new challenges, working with these tools at the forefront of discovery is an exciting opportunity to better understand tumor biology and improve clinical cancer care.” “Recent peer-reviewed publications demonstrate the importance of integrated genomics and the impact it can have on cancer research,” said Kevin King, president of Affymetrix. “Affymetrix is fully committed to providing tools to meet the evolving needs of the leading cancer researchers around the world.” Initial data from the studies will be released in the next three to six months. Speakers from the program can be heard at the integrated genomics conference series hosted by Affymetrix, beginning in mid-May. Speakers include Eileen Dolan of the University of Chicago, William Lin of Yale University and the Broad Institute of M.I.T. and Harvard and Sami Malek of the University of Michigan. Major events in the series will be held in New York City, Bethesda, Maryland, and Houston. “Our aim is to accelerate cancer research by providing scientists the most comprehensive view of the cancer genome, enabling them to focus their discovery, accurately identify candidate genes and accelerate their validation,” said Ruby Gadelrab, senior market development manager at Affymetrix and director of the program. As part of the program, Affymetrix is partially funding selected research projects that demonstrate clinical utility, in addition to helping participants obtain tools and training, and providing forums where investigators can exchange knowledge and share best practices. Later this year, Affymetrix is also expanding the Collaborations in Cancer Research Program across Asia-Pacific. The following is a partial listing of researchers participating in CCRP: Name :Tak Mak Wah Institute: University of Toronto, Department of Medical Biophysics Project: Copy number aberrations in breast and ovarian cancer Cancer Area: Breast and ovarian cancer Name : Sami Malek Institute: University of Michigan Project: Integrated genomic profiling to identify deregulated genes in genetic subtypes of acute myelogenous leukemia and CLL Cancer Area: Acute and chronic leukemia Name :William Lin Institute: Broad Institute of M.I.T. and Harvard Yale University, School of Medicine Project: Investigating the immunogenomic landscape in cutaneous T-cell lymphoma Cancer Area: Cutaneous T-cell lymphoma Name :Marc Ladanyi Institute: Memorial Sloan-Kettering Cancer Center Project: Integration of exon-level expression data and high-density genomic copy number data to screen for cancer gene fusions Cancer Area: Sarcomas, carcinomas Name :Robert Schneider Institute: New York University School of Medicine Cancer Institute Project: Genetic alterations in locally advanced and inflammatory breast cancer from FFPE tumor specimens Cancer Area: Breast cancer Name :Norman Lee Institute: George Washington University Medical Center, GW Cancer Institute Project: Oncogenomics of cancer disparities among racial minorities Cancer Area: Prostate genomics Name :John Hassell Institute: McMaster University Project: Expansion and propagation of breast cancer stem cells for genomic analyses Cancer Area: Breast cancer stem cells Name :Grover Bagby Institute: Oregon Health and Science University Project: Molecular pathogenesis of leukemic clonal evolution in fanconi anemia group C deficient mice Cancer Area: Acute myelogenous leukemia and myelodysplasia Name :Ian Campbell Institute: Peter MacCallum Cancer Centre, Melbourne, Australia Project: Integrated copy number/LOH, promoter methylation, miRNA and mina analysis of ovarian cancer. Cancer Area: Ovarian cancer Name :Loic Le Marchand Institute: University of Hawaii Project: Association of genetic variation with gene expression in colon cancer Cancer Area: Colon cancer Name :Benjamin Tycko Institute: Columbia University Project: MSNP for combined genetic and epigenetic profiling in cancer Cancer Area: Acute myeloid leukemia and breast cancer About Affymetrix Affymetrix GeneChip® microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases. Today, Affymetrix technology is used by the world’s top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,700 systems have been shipped around the world and more than 12,000 peer-reviewed papers have been published using the technology. Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Sacramento, Calif., Cleveland, Ohio, and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit the company’s website at www.affymetrix.com. Forward-looking Statements All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ “expectations,” “beliefs,” “hopes,” “intentions,” “strategies” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties relating to the outcome of the Collaborations in Cancer Research Program discussed in this press release; risks of the company’s ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses; uncertainties related to technological approaches, manufacturing and product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties related to sole-source suppliers; risks associated with acquisitions; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2007, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix’ expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. NOTE: Affymetrix, the Affymetrix logo and GeneChip® are registered trademarks owned or used by Affymetrix Inc.